Siemens Healthineers Nears the Exit Door: Tax Hurdle Cleared as Diagnostics Still Drags
Published on 08/06/2026 at 16:44 | Redaktion boerse-global.de
The separation of Siemens Healthineers from its parent company has moved from boardroom ambition to a calendar date. With tax authorities now having given binding clarity on the transaction's fiscal treatment, Siemens is pressing ahead with plans to hand roughly 30 percent of its Healthineers stake directly to its own shareholders. That distribution would cut Siemens' holding from around 67 percent today to below 40 percent, leaving the industrial giant with little more than a financial interest in the medtech business.
The mechanics are falling into place. A spin-off agreement is slated for completion by the end of this calendar year, with shareholders of both companies expected to vote on the deal at their annual meetings in the first quarter of 2027. The timetable gained further definition when CFO Veronika Bienert confirmed she would relinquish her seat on the Healthineers supervisory board at the February 2027 AGM — a move designed to underscore the subsidiary's growing independence. She joins CEO Roland Busch in stepping down, reducing Siemens' board representation from three members to one. Ralf Thomas remains chairman despite leaving the Siemens executive board, a detail analysts read as confirmation that the operational uncoupling is proceeding on schedule.
A One-Off Payment Masks a Softer Core
The latest quarterly numbers, covering the period through June 30, illustrate just how uneven the underlying business has become. Imaging, the flagship segment, posted comparable growth of 2.3 percent, while precision therapy advanced a robust 9.2 percent. Diagnostics, however, remains the sore spot: revenue there fell 5.5 percent, weighed down by persistently weak demand in China. Group-wide organic growth came in at 2.8 percent.
Despite that mixed performance, management raised its full-year earnings guidance. Adjusted earnings per share are now expected to land between EUR 2.35 and EUR 2.45, up from a prior range of EUR 2.20 to EUR 2.30. The upgrade, however, owes little to operational momentum. Following binding rulings in the US, the company is entitled to recover duties previously paid under the International Emergency Economic Powers Act — a windfall that flatters the bottom line while the revenue outlook was simultaneously trimmed to comparable growth of just 3.5 to 4.0 percent. For diagnostics specifically, this marks the second guidance cut within a year, a telling sign that the anticipated Chinese recovery has yet to materialize.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Bulls and Bears Stake Out Their Positions
The equity story has enjoyed a strong run in recent weeks, with the shares changing hands around EUR 39.32 — nearly dead on their 200-day moving average of EUR 39.31. Over the past month, the stock has climbed 11.7 percent. Yet the relative strength index, at 73.7, now flags an overbought condition, a cautionary note for those chasing the move at these levels.
Analyst sentiment is split along familiar lines. JPMorgan's David Adlington lifted his price target on Monday from EUR 54.30 to EUR 57.40, maintaining an "Overweight" rating on the back of higher sector valuation multiples. The ten-year strategic alliance with the Cleveland Clinic announced last Friday, focused on joint development of clinical imaging innovations, adds further weight to the bull case beyond the diagnostics troubles. Bernstein Research, by contrast, trimmed its own target from EUR 45.70 to EUR 44.50 on Tuesday, keeping an "Outperform" rating but pointing squarely at China as the principal source of delay.
Supporting the share price from underneath is the ongoing buyback program. Since its launch on June 1, 2026, Healthineers has repurchased over 2.7 million of its own shares, including 48,278 in the week through August 2. A company that keeps buying back stock even while cutting its diagnostics outlook is signaling confidence in its medium-term valuation — or at least a willingness to back that confidence with cash.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
What Happens Next
The near-term catalyst calendar is now clearly marked. On November 5, fourth-quarter and full-year 2026 results will reveal whether diagnostics has finally found its floor — a data point that may matter more for the share price than any spin-off headline. The more consequential moment arrives in February 2027, when shareholders vote on the deconsolidation and Bienert's board exit takes effect.
The bull case rests on imaging and precision therapy maintaining their growth trajectory, the buyback continuing to provide a bid, and the market eventually re-rating Healthineers as a standalone medtech story once the conglomerate discount disappears. The bear case is equally straightforward: the one-time US tariff refund that flattered this year's numbers will not repeat in 2027, and if diagnostics has not turned by then, further guidance revisions could quickly erase the recent gains. With the RSI already signaling stretched conditions, much of the good news — buybacks, target upgrades, spin-off progress — may already be in the price. A detailed post-separation strategy is expected in the fourth calendar quarter, which should give investors a clearer sense of what life looks like on the other side of the split.
Ad
Siemens Healthineers Stock: New Analysis - 6 August
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
